(function(){
			var content_array=["<p><strong>About DOTATOC<\/strong><\/p>\r\n<p>DOTATOC or Edotreotide is a superior synthetic somatostatin analog  which binds perfectly to somatostatin receptors predominantly  overexpressed in neuroendocrine tumors (NETs). NETs are rare kind of  tumors which arise from neuroendocrine cells and may occur in different  parts of the body.<\/p>\r\n<p>DOTA-chelated peptide Edotreotide exhibits excellent pharmacokinetic  properties and can be efficiently radiolabeled with medical  radionuclides. Its excellent therapeutic properties have been  successfully started in various clinical trials.<\/p>\r\n<p><strong>About ITM Isotope Technologies Munich AG<\/strong><\/p>\r\n<p>The&nbsp;itm Group is the leading company for the development, production  and worldwide distribution of highly effective radionuclides for  diagnosis and therapy as well as radionuclide-based medical devices. Its  commitment to shaping the future of theranostics is built on robust  platform technologies and innovative new generation radioisotopes which  assure safety, performance and security of supply!<\/p>\r\n<p><strong>Contacts<\/strong><\/p>\r\n<p>Christopher Morin<br \/> Manager Marketing &amp; Corporate Communications<br \/> Phone: +49-89-289-13915<br \/> Mail: <a rel=\"nofollow\" href=\"mailto:Christopher.Morin@itg-garching.de\" target=\"_blank\">Christopher.Morin@itg-garching.de<\/a><\/p>\r\n<p>Steffen Schuster<br \/> CEO<br \/> Phone: +49-89-289-13970<br \/> Mail: <a rel=\"nofollow\" href=\"mailto:Steffen.Schuster@itm.ag\" target=\"_blank\">Steffen.Schuster@itm.ag<\/a><\/p>\r\n<p><strong>ITM Isotope Technologies Munich AG<\/strong><\/p>\r\n<p>Aufsichtsratsvorsitzender - Udo J. Vetter, Vorstandsvorsitzender -  Steffen Schuster, Sitz der Gesellschaft - Lichtenbergstr. 1, 85748  Garching - HG Munchen - HRB 154944<\/p>"];
			$("#dvExtra").html(content_array[0]);})();